Sunday, March 27, 2011

Five years on breast cancer drug tamoxifen beats two

NEW YORK (Reuters Health) – A new study has a bit of good news for most women who've had breast cancer surgery.

It turns out that sticking with the older and relatively cheap drug tamoxifen for the recommended 5 years instead of just 2 will cut the risk of having the cancer return.

And there is an added bonus: For women in their 50s, the longer drug treatment also reduced the chance they'd develop heart disease.

"That little

Read more ...

No comments:

Post a Comment